OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes
OptiBiotix Health plc (AIM: OPTI) Notice of Annual General Meeting
OptiBiotix Health plc (AIM: OPTI) reported strong revenue and margin growth in its audited results for 2025 as the company continued expanding international sales of its weight management and gut
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF) SweetBiotix® Sampling
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes
OptiBiotix Health secures large order, sees record early 2026 demand
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes,
OptiBiotix Health plc (AIM: OPTI) Launch of SlimBiome® in leading US brand
OptiBiotix Health plc (AIM: OPTI), a life sciences company focused on products that reduce hunger and food cravings, improve the gut microbiome, and offer sweet fibres as healthy sugar alternatives,
OptiBiotix Health – SlimBiome® study in European Journal of Nutrition
New SlimBiome® study published in European Journal of Nutrition
OptiBiotix Health jumped 10% in early trading on Tuesday on First order from US News
First order from leading US weight management brand
OptiBiotix Health (AIM:OPTI) reports strong commercial progress for 2024
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, provides the
OptiBiotix Health (AIM:OPTI) Launch of Daily Nouri FeelFull product in America
Launch of Daily Nouri FeelFull product in America SlimBiome® containing finished products
OptiBiotix Health (AIM:OPTI) Requisition update
OptiBiotix Health plc (AIM: OPTI) (“OptiBiotix”) the life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, advises that in relation to the requisitioned general meeting of
OptiBiotix Health (AIM:OPTI) SlimBiome study update
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces further positive study results.
Share Talk Weekly Small Cap Movers & Shakers, Saturday 27th July 2024
The FTSE 100 closed higher on Friday gaining an encouraging 1.2%. The top performer was NatWest, which rose by 7%, followed by Anglo American with a 5.1% increase.